Harriet M Kluger

Harriet M Kluger

UNVERIFIED PROFILE

Are you Harriet M Kluger?   Register this Author

Register author
Harriet M Kluger

Harriet M Kluger

Publications by authors named "Harriet M Kluger"

Are you Harriet M Kluger?   Register this Author

100Publications

2340Reads

13Profile Views

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.

J Immunother Cancer 2019 Sep 18;7(1):254. Epub 2019 Sep 18.

Department of Pathology, Yale University School of Medicine, 310 Cedar Street, PO Box 208023, New Haven, CT, 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0731-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751819PMC
September 2019

Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors.

Int J Radiat Oncol Biol Phys 2019 Aug 31. Epub 2019 Aug 31.

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT; Department of Neurosurgery, Yale School of Medicine, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.08.053DOI Listing
August 2019

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.

Ophthalmology 2019 Jul 6;126(7):1058-1062. Epub 2019 Feb 6.

Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut; Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ophtha.2019.01.031DOI Listing
July 2019

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.

J Immunother Cancer 2019 Jul 23;7(1):194. Epub 2019 Jul 23.

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0675-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651990PMC
July 2019

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.

J Immunother Cancer 2019 Jul 30;7(1):200. Epub 2019 Jul 30.

Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0684-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668163PMC
July 2019

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.

J Immunother Cancer 2019 Jun 14;7(1):153. Epub 2019 Jun 14.

Departments of Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0613-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567557PMC
June 2019

Reply to A. Shinde et al.

J Clin Oncol 2019 Apr 26;37(12):1031-1032. Epub 2019 Feb 26.

Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02463
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02463DOI Listing
April 2019

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

Cell Rep 2019 Apr;27(4):1277-1292.e7

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA; Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.03.085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592283PMC
April 2019

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

J Immunother Cancer 2018 11 27;6(1):131. Epub 2018 Nov 27.

Department of Medicine, Divisions of Dermatology and Medical Oncology, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0450-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258401PMC
November 2018

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

Cancer J 2017 Jan/Feb;23(1):1-2

From the Section of Medical Oncology, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526070PMC
October 2018

Anti-PD-1 Therapy-Associated Perforating Colitis.

Case Rep Gastrointest Med 2018 31;2018:3406437. Epub 2018 May 31.

Department of Pathology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3406437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000840PMC
May 2018

Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.

J Immunother 2017 10;40(8):307-311

*Department of Surgery, Section of Surgical Oncology †Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine ‡Department of Internal Medicine, Section of Medical Oncology Departments of §Dermatology ∥Pathology, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000181DOI Listing
October 2017

Comparing available criteria for measuring brain metastasis response to immunotherapy.

J Neurooncol 2017 05 8;132(3):479-485. Epub 2017 Mar 8.

Department of Therapeutic Radiology, Yale School of Medicine, 333 Cedar St, New Haven, CT, 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2398-8DOI Listing
May 2017

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Br J Cancer 2017 Feb 19;116(4):432-440. Epub 2017 Jan 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318966PMC
February 2017

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

Cancer 2016 10 10;122(19):3051-8. Epub 2016 Jun 10.

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030143PMC
October 2016

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Curr Oncol Rep 2016 09;18(9):57

Section of Medical Oncology, Department of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, 06510, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0542-9DOI Listing
September 2016

MET Inhibition in Clear Cell Renal Cell Carcinoma.

J Cancer 2016 18;7(10):1205-14. Epub 2016 Jun 18.

1. Department of Urology, Yale School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.14604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934028PMC
July 2016

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

Cancer Immunol Res 2016 Jun 18;4(6):481-7. Epub 2016 Mar 18.

Department of Neurosurgery, Yale University, School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0238DOI Listing
June 2016

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

N Engl J Med 2016 Jun 19;374(26):2542-52. Epub 2016 Apr 19.

From the University of Washington Medical Center (P.T.N., S. Bhatia, N.J.M., E.M.S., M.M.S., J.A.T., M.A.C.), Fred Hutchinson Cancer Research Center (P.T.N., S. Bhatia, S.P.F., L.L., J.A.T., M.A.C.), Cancer Immunotherapy Trials Network (S.P.F., L.L., M.A.C.), and Cancer Research and Biostatistics (A.M., L.R.S.) - all in Seattle; Johns Hopkins University School of Medicine and Kimmel Cancer Center, Baltimore (E.J.L., S. Berry, D.M.P., W.H.S., J.C.S., J.M.T., S.L.T.), and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda. (E.S.) - both in Maryland; Winship Cancer Institute of Emory University, Atlanta (R.R.K.); Merck Research Laboratories, Kenilworth, NJ (L.A., E.K.C., S.M.T., J.H.Y.); University of California, San Francisco, San Francisco (A.D.), and Stanford University, Stanford (H.E.K., K.M., S.A.R.) - both in California; Mt. Sinai Medical Center, New York (P.A.F.); Yale University, New Haven, CT (H.M.K.); and Ohio State University, Columbus (T.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927341PMC
June 2016

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Cancer Immunol Res 2016 Mar 23;4(3):179-82. Epub 2015 Dec 23.

Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881844PMC
March 2016

Systemic Immunotherapy for the Treatment of Brain Metastases.

Front Oncol 2016 9;6:49. Epub 2016 Mar 9.

Section of Medical Oncology, Department of Medicine, Yale Cancer Center , New Haven, CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783384PMC
March 2016

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Proc Natl Acad Sci U S A 2016 Feb 10;113(8):2170-5. Epub 2016 Feb 10.

Department of Pathology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1525735113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776463PMC
February 2016

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

Clin Cancer Res 2016 Jan 25;22(2):374-82. Epub 2015 Aug 25.

Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821426PMC
January 2016

Clinical trials in melanoma patients with brain metastases.

Pigment Cell Melanoma Res 2015 Nov 20;28(6):741-3. Epub 2015 Aug 20.

Medicine, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834841PMC
November 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Clin Cancer Res 2015 May 14;21(9):2138-47. Epub 2014 Oct 14.

Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397107PMC
May 2015

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

Oncotarget 2014 Jul;5(14):5209-17

Yale Cancer Center, Yale University School of Medicine, New Haven, CT, U.S.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170640PMC
http://dx.doi.org/10.18632/oncotarget.2101DOI Listing
July 2014

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Clin Cancer Res 2014 Jun 8;20(12):3328-37. Epub 2014 Apr 8.

Authors' Affiliations: Hematology/Oncology, Department of Medicine, University of Pennsylvania; Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania, Philadelphia; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Yale University School of Medicine; and Section of Medical Oncology, Yale Cancer Center, New Haven, ConnecticutAuthors' Affiliations: Hematology/Oncology, Department of Medicine, University of Pennsylvania; Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania, Philadelphia; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; Dana Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Yale University School of Medicine; and Section of Medical Oncology, Yale Cancer Center, New Haven, Connecticut

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058354PMC
June 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

MEK targeting in N-RAS mutated metastatic melanoma.

Mol Cancer 2014 Mar 4;13:45. Epub 2014 Mar 4.

Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, WWW213, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945937PMC
March 2014

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

Cancer Cell Int 2014 Jan 14;14(1). Epub 2014 Jan 14.

Departments of Medicine, Section of Medical Oncology, Yale University School of Medicine, 333 Cedar St., WWW213, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1475-2867-14-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896780PMC
January 2014

Advances in therapy for melanoma brain metastases.

Clin Dermatol 2013 May-Jun;31(3):264-81

Department of Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2012.08.008DOI Listing
November 2013

Radiation sensitivity and sensitization in melanoma.

Pigment Cell Melanoma Res 2013 Nov 12;26(6):928-30. Epub 2013 Aug 12.

Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866027PMC
November 2013

Advances in the systemic treatment of metastatic melanoma.

Oncology (Williston Park) 2013 May;27(5):374-81

Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092183PMC
May 2013

Drug targets and predictive biomarkers in the management of metastatic melanoma.

Pharmgenomics Pers Med 2012 28;5:139-48. Epub 2012 Sep 28.

Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S25100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513235PMC
April 2013

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.

Breast Cancer Res 2010 1;12(5):R66. Epub 2010 Sep 1.

Department of Cell Biology, New York University Center for Health Informatics and Bioinformatics, New York University School of Medicine and Cancer Institute, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2633DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096952PMC
February 2013

Vertical pathway targeting in cancer therapy.

Adv Pharmacol 2012 ;65:1-26

Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-397927-8.00001-4DOI Listing
February 2013

Studies of NVP-BEZ235 in melanoma.

Curr Cancer Drug Targets 2013 Feb;13(2):165-74

Section of Medical Oncology, 333 Cedar Street, New Haven, Connecticut, 06520, USA.

View Article

Download full-text PDF

Source
February 2013

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

BMC Clin Pathol 2013 Feb 1;13. Epub 2013 Feb 1.

Department of Medicine and Yale Cancer Center, 333 Cedar St,, WWW213, New Haven, CT, 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6890-13-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575219PMC
February 2013

Vascularity of primary and metastatic renal cell carcinoma specimens.

J Transl Med 2013 Jan 14;11:15. Epub 2013 Jan 14.

Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-11-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561185PMC
January 2013

Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Curr Oncol Rep 2012 Oct;14(5):449-57

The Cancer Institute of New Jersey, 195 Little Albany Street Rm 5543, New Brunswick, NJ 08903, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-012-0249-5
Publisher Site
http://dx.doi.org/10.1007/s11912-012-0249-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447200PMC
October 2012

CD70 expression patterns in renal cell carcinoma.

Hum Pathol 2012 Sep 7;43(9):1394-9. Epub 2012 Mar 7.

Department of Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2011.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374042PMC
September 2012

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

J Neurosurg 2012 Aug 15;117(2):227-33. Epub 2012 Jun 15.

Department of Radiation Medicine, Hofstra University North Shore-LIJ School of Medicine, Hofstra University, Manhasset, New York 11030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2012.5.JNS111929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098938PMC
August 2012

Immunotherapy for metastatic melanoma.

J Cell Biochem 2012 Mar;113(3):725-34

Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, Connecticut 06451, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.23402
Publisher Site
http://dx.doi.org/10.1002/jcb.23402DOI Listing
March 2012

Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.

J Clin Oncol 2011 Nov 11;29(32):e792-4. Epub 2011 Oct 11.

Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.36.9199DOI Listing
November 2011

A phase 2 trial of dasatinib in advanced melanoma.

Cancer 2011 May 29;117(10):2202-8. Epub 2010 Nov 29.

Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116034PMC
May 2011

Plasma markers for identifying patients with metastatic melanoma.

Clin Cancer Res 2011 Apr 12;17(8):2417-25. Epub 2011 Apr 12.

Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415234PMC
April 2011

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Clin Cancer Res 2010 Dec;16(24):6029-39

Department of Pathology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1490DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058635PMC
December 2010

Ipilimumab: a promising immunotherapy for melanoma.

Oncology (Williston Park) 2010 Dec;24(14):1280-8

Yale Cancer Center, Yale School of Medicine, New Haven, CT 06451, USA.

View Article

Download full-text PDF

Source
December 2010

Chemotherapy and biologic therapies for melanoma: do they work?

Clin Dermatol 2009 Nov-Dec;27(6):614-25

Department of Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2008.09.020DOI Listing
January 2010

Melanoma prognostic model using tissue microarrays and genetic algorithms.

J Clin Oncol 2009 Dec 2;27(34):5772-80. Epub 2009 Nov 2.

Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.8239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792999PMC
December 2009

C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Clin Cancer Res 2009 Sep 8;15(18):5704-13. Epub 2009 Sep 8.

Yale Cancer Center and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763114PMC
September 2009

Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.

Clin Cancer Res 2009 May 21;15(9):3029-36. Epub 2009 Apr 21.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431617PMC
May 2009

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.

Lab Invest 2008 Sep 14;88(9):962-72. Epub 2008 Jul 14.

Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/labinvest200865
Publisher Site
http://dx.doi.org/10.1038/labinvest.2008.65DOI Listing
September 2008

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

Breast Cancer Res 2008 23;10(2):R35. Epub 2008 Apr 23.

Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr1998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397537PMC
July 2008

Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

Clin Cancer Res 2008 Jul;14(14):4455-62

Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849429PMC
July 2008

Assessing expression of apoptotic markers using large cohort tissue microarrays.

Methods Mol Biol 2008 ;414:83-93

Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-59745-339-4_8DOI Listing
February 2008

High HSP90 expression is associated with decreased survival in breast cancer.

Cancer Res 2007 Apr;67(7):2932-7

Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-4511DOI Listing
April 2007

Rab33A: characterization, expression, and suppression by epigenetic modification.

J Invest Dermatol 2006 Oct 29;126(10):2257-71. Epub 2006 Jun 29.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520-8059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.jid.5700386DOI Listing
October 2006

Characterizing disease states from topological properties of transcriptional regulatory networks.

BMC Bioinformatics 2006 May 2;7:236. Epub 2006 May 2.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2105-7-236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482723PMC
May 2006

Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.

Lancet Oncol 2006 Mar;7(3):270-1

Section of Medical Oncology, Yale Comprehensive Cancer Center, 333 Cedar Street, PO Box 208032, New Haven, CT 06520-8032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(06)70619-2DOI Listing
March 2006

Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.

Clin Cancer Res 2005 Jul;11(14):5188-94

Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-05-0158DOI Listing
July 2005